Newsroom
Engineered Immunotherapies for Solid Tumors
How leading developers are rethinking strategy, execution, and risk in engineered immunotherapy programs for solid tumors. Engineered immune therapies represent the next…
Support for psychological well-being with clinically…
In a six-week clinical trial (N=596), adults supplementing with 200 mg/day of ButyraGen experienced statistically significant improvements in measures of…
Outsourced Pharma Capabilities Update: Cell & Gene Therapy
March 12, 2026 | 11AM ET Watch leading CDMOs share current capabilities, locations, timelines, and available capacity for cell and…
Is Your Food Traceability Plan FSMA Section 204(d)…
Walt Goodfield recently met with a USFDA Compliance & Enforcement Officer at a regional Institute of Food Technologists (IFT) networking…
Top market strategies for today's pharma landscape
The complexity of turning a new drug into a successful asset remains a hurdle even beyond the coveted FDA approval.…
Preparing Pharma for 2026 Disruptions
Learn how AI innovation, drug approvals, and regulatory shifts will influence strategy and investment next year. Pharma executives are entering…